BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24687512)

  • 1. In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.
    Gavrish E; Shrestha B; Chen C; Lister I; North EJ; Yang L; Lee RE; Han A; Williams B; Charnuska D; Coleman K; Lewis K; LaFleur MD
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3255-60. PubMed ID: 24687512
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Huang Y; Hang X; Jiang X; Zeng L; Jia J; Xie Y; Li F; Bi H
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936098
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective killing of
    Xiong M; Bao Y; Xu X; Wang H; Han Z; Wang Z; Liu Y; Huang S; Song Z; Chen J; Peek RM; Yin L; Chen LF; Cheng J
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):12675-12680. PubMed ID: 29133389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model.
    Narayana JL; Huang HN; Wu CJ; Chen JY
    Biomaterials; 2015 Aug; 61():41-51. PubMed ID: 25996410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activities of peptide Cbf-K
    Jiang M; Ma L; Huang Y; Wu H; Dou J; Zhou C
    Microb Pathog; 2020 Jan; 138():103847. PubMed ID: 31704464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Helicobacter pylori potential of artemisinin and its derivatives.
    Goswami S; Bhakuni RS; Chinniah A; Pal A; Kar SK; Das PK
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4594-607. PubMed ID: 22687518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Helicobacter pylori activities of Chenopodium ambrosioides L. in vitro and in vivo.
    Ye H; Liu Y; Li N; Yu J; Cheng H; Li J; Zhang XZ
    World J Gastroenterol; 2015 Apr; 21(14):4178-83. PubMed ID: 25892867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.
    Kouitcheu Mabeku LB; Eyoum Bille B; Tepap Zemnou C; Tali Nguefack LD; Leundji H
    BMC Infect Dis; 2019 Oct; 19(1):880. PubMed ID: 31640588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice.
    De R; Kundu P; Swarnakar S; Ramamurthy T; Chowdhury A; Nair GB; Mukhopadhyay AK
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1592-7. PubMed ID: 19204190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
    Lee JW; Kim N; Nam RH; Lee SM; Soo In C; Kim JM; Lee DH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):666-672. PubMed ID: 30726563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
    Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
    Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice.
    De R; Sarkar A; Ghosh P; Ganguly M; Karmakar BC; Saha DR; Halder A; Chowdhury A; Mukhopadhyay AK
    J Antimicrob Chemother; 2018 Jun; 73(6):1595-1603. PubMed ID: 29566160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of Helicobacter pylori infection.
    Costa F; D'Elios MM
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):887-92. PubMed ID: 20695744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo bactericidal activity of Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo and its main effective component, palmatine, against porcine Helicobacter pylori.
    Rong Q; Xu M; Dong Q; Zhang Y; Li Y; Ye G; Zhao L
    BMC Complement Altern Med; 2016 Aug; 16(1):331. PubMed ID: 27576439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Helicobacter pylori infected mice with Bryophyllum pinnatum, a medicinal plant with antioxidant and antimicrobial properties, reduces bacterial load.
    Kouitcheu Mabeku LB; Eyoum Bille B; Tchouangueu TF; Nguepi E; Leundji H
    Pharm Biol; 2017 Dec; 55(1):603-610. PubMed ID: 27937097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of Helicobacter pylori infection: current status].
    Wagner S; Gebel M; Manns M
    Z Gastroenterol; 1993; 31(7-8):459-63. PubMed ID: 8379235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin for Helicobacter pylori infection.
    Leung WK; Graham DY
    Expert Opin Pharmacother; 2000 Mar; 1(3):507-14. PubMed ID: 11249534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.